Molecular theranostics: A primer for the imaging professional

Daniel Y. Lee, King C.P. Li

Research output: Contribution to journalReview article

Abstract

OBJECTIVE. A theranostic system integrates some form of diagnostic testing to determine the presence of a molecular target for which a specific drug is intended. Molecular imaging serves this diagnostic function and provides powerful means for noninvasively detecting disease. We briefly review the paradigms rooted in nuclear medicine and highlight recent advances in this field. We also explore how nanometer-sized complexes, called nanomedicines, present an excellent theranostic platform applicable to both drug discovery and clinical use. CONCLUSION. For imagers, molecular theranostics represents a powerful emerging platform that intimately couples targeted therapeatic entities with noninvasive imaging that yields information on the presence of defined molecular targets before, during, and after cognate therapy.

Original languageEnglish (US)
Pages (from-to)318-324
Number of pages7
JournalAmerican Journal of Roentgenology
Volume197
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Nanomedicine
Molecular Imaging
Nuclear Medicine
Drug Discovery
Pharmaceutical Preparations
Theranostic Nanomedicine
Therapeutics

Keywords

  • Cancer therapy
  • Molecular imaging
  • Molecular medicine
  • Nanomedicine
  • Theranostics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Molecular theranostics : A primer for the imaging professional. / Lee, Daniel Y.; Li, King C.P.

In: American Journal of Roentgenology, Vol. 197, No. 2, 01.08.2011, p. 318-324.

Research output: Contribution to journalReview article

@article{d335daed8ebe426692001c0c3aad962e,
title = "Molecular theranostics: A primer for the imaging professional",
abstract = "OBJECTIVE. A theranostic system integrates some form of diagnostic testing to determine the presence of a molecular target for which a specific drug is intended. Molecular imaging serves this diagnostic function and provides powerful means for noninvasively detecting disease. We briefly review the paradigms rooted in nuclear medicine and highlight recent advances in this field. We also explore how nanometer-sized complexes, called nanomedicines, present an excellent theranostic platform applicable to both drug discovery and clinical use. CONCLUSION. For imagers, molecular theranostics represents a powerful emerging platform that intimately couples targeted therapeatic entities with noninvasive imaging that yields information on the presence of defined molecular targets before, during, and after cognate therapy.",
keywords = "Cancer therapy, Molecular imaging, Molecular medicine, Nanomedicine, Theranostics",
author = "Lee, {Daniel Y.} and Li, {King C.P.}",
year = "2011",
month = "8",
day = "1",
doi = "10.2214/AJR.11.6797",
language = "English (US)",
volume = "197",
pages = "318--324",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "2",

}

TY - JOUR

T1 - Molecular theranostics

T2 - A primer for the imaging professional

AU - Lee, Daniel Y.

AU - Li, King C.P.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - OBJECTIVE. A theranostic system integrates some form of diagnostic testing to determine the presence of a molecular target for which a specific drug is intended. Molecular imaging serves this diagnostic function and provides powerful means for noninvasively detecting disease. We briefly review the paradigms rooted in nuclear medicine and highlight recent advances in this field. We also explore how nanometer-sized complexes, called nanomedicines, present an excellent theranostic platform applicable to both drug discovery and clinical use. CONCLUSION. For imagers, molecular theranostics represents a powerful emerging platform that intimately couples targeted therapeatic entities with noninvasive imaging that yields information on the presence of defined molecular targets before, during, and after cognate therapy.

AB - OBJECTIVE. A theranostic system integrates some form of diagnostic testing to determine the presence of a molecular target for which a specific drug is intended. Molecular imaging serves this diagnostic function and provides powerful means for noninvasively detecting disease. We briefly review the paradigms rooted in nuclear medicine and highlight recent advances in this field. We also explore how nanometer-sized complexes, called nanomedicines, present an excellent theranostic platform applicable to both drug discovery and clinical use. CONCLUSION. For imagers, molecular theranostics represents a powerful emerging platform that intimately couples targeted therapeatic entities with noninvasive imaging that yields information on the presence of defined molecular targets before, during, and after cognate therapy.

KW - Cancer therapy

KW - Molecular imaging

KW - Molecular medicine

KW - Nanomedicine

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=79960718639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960718639&partnerID=8YFLogxK

U2 - 10.2214/AJR.11.6797

DO - 10.2214/AJR.11.6797

M3 - Review article

C2 - 21785076

AN - SCOPUS:79960718639

VL - 197

SP - 318

EP - 324

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 2

ER -